Hepatitis-C cost of care $1 Trillion by 2010

Healthcare reform and Personalized medicine
 877_ 8/3/10- In this [part 3 of 3] interview with Dr. Timothy Rodell, President and CEO, GlobeImmune, Larry brought up 'healthcare reform'. Dr. Rodell replied, "I think this a critical thing for people to understand. It's important to me as a physician and it's hugely important to the country. Wherever you stand with respect to the political spectrum, it is impossible to conclude that being able to deliver appropriate healthcare to the maximum number of people is critical from a public health perspective, and it's also critical from an economic perspective. And I think the point that it's important for us all to understand, is that adequate delivery of high level and scientifically validated healthcare is going to have both a positive economic impact and a positive impact on public health. Using hepatitis-C as an example, Chronic Hepatitis-C infection is the primary cause in the developed world of liver cancer and the primary thing that makes patients require liver transplants. As you can imagine both of those are extremely expensive conditions to treat. So if we can improve, increase the percentage of patients that we can cure, this is hugely important and hugely economically important. To give you an idea of the magnitude of what this means, it's been estimated that the cost of taking care of patients in the U.S. with chronic hepatitis-C infection, between now and 2020, is one trillion dollars. So if we can develop therapies that improve the outcomes in those 60% of patients that don't respond to our current treatment, the impact is going to be gigantic. In fact, if we can improve it for all of those patients, the impact would be enough essentially to pay for healthcare reform. The second issue is transferring great academic research into private companies like GlobeImmune..." Listen for more...
Related Links: GlobeImmune || CU Technology Transfer Office || CU TTO Channel || TTO Blog || Podcast Directory || Keywords: Dr, Timothy Rodell, GlobeImmune, Healthcare Reform, Chronic Hepatitis C (HCV) Infection, University of Colorado, Tech Transfer, VCs, Liver Cancer, T Cell, Pharmaceutical Companies, Dave Allen 8/3/10 Chnl: CUTTO bytes: 5910050 Listen to: Dr. Timothy Rodell, GlobeImmune Part 3 of 3

Powered by Podbean.com